NCT00096811View on ClinicalTrials.gov

Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program

NO_LONGER_AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

September 30, 2003

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Hepatitis BChronic Disease
Interventions
DRUG

Entecavir

Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.

Trial Locations (5)

13110

Local Institution, Safed

16100

Local Institution, Nazareth

49100

Local Institution, Petah Tikva

64239

Local Institution, Tel Aviv

91120

Local Institution, Jerusalem

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00096811 - Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program | Biotech Hunter | Biotech Hunter